Provided by Tiger Trade Technology Pte. Ltd.

CUTIA-B

0.850
-0.020-2.30%
Volume:310.20K
Turnover:261.96K
Market Cap:317.05M
PE:-0.83
High:0.870
Open:0.870
Low:0.810
Close:0.870
52wk High:9.190
52wk Low:0.740
Shares:373.00M
HK Float Shares:373.00M
Volume Ratio:0.46
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.030
ROE:-38.30%
ROA:-14.05%
PB:0.38
PE(LYR):-0.83
PS:0.81

Loading ...

Cutia-B obtains NMPA marketing nod for CU-30101 lidocaine-tetracaine topical anesthetic

Bulletin Express
·
May 07

Cutia Therapeutics says NMPA approves CU-30101 topical lidocaine-tetracaine cream

Reuters
·
May 07

Cutia Therapeutics - Cu-30101 Obtains Drug Marketing Authorization by Nmpa in China

THOMSON REUTERS
·
May 07

Fidelity China Fund Boosts Stake in Cutia-B with 30,600 Share Purchase

Stock News
·
Apr 28

Cutia Therapeutics Updates Cayman Registrar Name to Ascentium (Cayman) Limited

Bulletin Express
·
Apr 27

Cutia Therapeutics 2025年度简讯:收入同比增20.2%至3.362亿人民币,核心皮肤科产品商业化显著提升业绩

Bulletin Express
·
Apr 24

Cutia Posts RMB336.20 Million Revenue; ESG Drive Cuts Carbon Intensity 16.67 %

Bulletin Express
·
Apr 24

CUTIA-B schedules 26 Jun 2026 AGM to approve board renewals, 10% buyback and 20% issuance mandates

Bulletin Express
·
Apr 24

Cutia Therapeutics announces annual general meeting

Reuters
·
Apr 24

Cutia Therapeutics publishes 2025 annual report

Reuters
·
Apr 24

CUTIA-B Shares Climb Over 3% Following Completion of Phase III Trial for Injectable Botulinum Toxin

Stock News
·
Apr 13

Cutia Therapeutics completes China Phase III trial of CU-20101 for glabellar lines

Reuters
·
Apr 13

Cutia Therapeutics Completes Phase 3 Trial for Botulinum Toxin Product

MT Newswires Live
·
Apr 13

BRIEF-Cutia Therapeutics Says Completion Of Phase III Clinical Trial Of Cu-20101

Reuters
·
Apr 13

CUTIA-B Completes Phase III Trial in China for Botulinum Toxin Type A Injection Targeting Glabellar Lines

Stock News
·
Apr 13

Cutia Therapeutics - Completion of Phase Iii Clinical Trial of Cu-20101

THOMSON REUTERS
·
Apr 13